DDInter298 DDInter1105
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) treats {v} (Disease) brain cancer
brain cancer {u} (Disease) is palliated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carboplatin (Compound) treats brain cancer (Disease) and brain cancer (Disease) is palliated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Lurbinectedin
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Lurbinectedin
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Carboplatin (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Lurbinectedin